Small-cell Lung Cancer Clinical Trial
Official title:
A Randomized Phase II Trial of Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin in Combination With Concurrent Thoracic Radiotherapy for Patients With Limited Small-cell Lung Cancer
This randomized phase II study compare survival outcomes and toxicity of two chemotherapy regimens (etoposide plus lobaplatin or etoposide plus cisplatin) in combination with concurrent thoracic radiation therapy (TRT) for limited stage small cell lung cancer.
Lobaplatin is a platinum complex with DNA alkylating activity that was developed by ASTA Medica (Degussa) for the treatment of cancer. Lobaplatin as the third-generation platinum antineoplastic agent, showed promising antineoplastic effects in variety of preclinical test tumor models. A randomized, multicenter phase III study showed that Lobaplatin plus etoposide (EL) regimen is not inferiority to cisplatin plus etoposide (EP) regimen in terms of PFS, the tolerance and QOL with EL regimen are better than that with EP regimen. Thus, we perform this study was to compare the efficacy and safety of EL and EP regimens concurrently with thoracic radiotherapy in patients with limited-stage SCLC. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05552846 -
Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
|
Phase 2 | |
| Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
| Recruiting |
NCT06022757 -
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04923776 -
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
|
Phase 2 | |
| Recruiting |
NCT04168281 -
Watchful Observation of Patients With LD-SCLC Instead of the PCI
|
N/A | |
| Completed |
NCT03239171 -
Bioinformation Therapy for Lung Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06457906 -
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
|
Phase 3 | |
| Recruiting |
NCT04539977 -
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03345485 -
Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06103682 -
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
|
N/A | |
| Recruiting |
NCT04170946 -
Talazoparib and Thoracic RT for ES-SCLC
|
Phase 1 | |
| Recruiting |
NCT03523234 -
Neoadjuvant Therapy Combined With Radical Surgery for the Treatment of Small Cell Lung Cancer (SCLC) in II and IIIA Stage
|
N/A | |
| Recruiting |
NCT05620134 -
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05578326 -
Study of Trilaciclib and Lurbinectidin
|
Phase 2 | |
| Recruiting |
NCT06255197 -
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
|
||
| Terminated |
NCT04610658 -
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
|
Phase 1 | |
| Active, not recruiting |
NCT04116320 -
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT05091567 -
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
|
Phase 3 | |
| Terminated |
NCT04596033 -
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
|
Phase 1 |